Expression of RABEX-5 and its clinical significance in prostate cancer

Journal of Experimental and Clinical Cancer Research

Volumn 33, Issue 1, 2014, Pages

  Zhang, Hongtuan ^a   Cheng, Shang ^a   Wang, Andi ^a   Ma, Hui ^a   Yao, Bing ^a   Qi, Can ^a   Liu, Ranlu ^a   Qi, Shiyong ^a   Xu, Yong ^a  

^a SECOND HOSPITAL OF TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MEMBRANE PROTEIN; MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN; RABEX 5 PROTEIN; UNCLASSIFIED DRUG;

AGED; ARTICLE; BIOCHEMICAL RECURRENCE FREE SURVIVAL; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURGERY; CANCER TISSUE; DISEASE ASSOCIATION; DISEASE SEVERITY; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SURVIVAL PREDICTION; UPREGULATION;

AGED; DISEASE-FREE SURVIVAL; GENE EXPRESSION; GUANINE NUCLEOTIDE EXCHANGE FACTORS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATE; PROSTATECTOMY; PROSTATIC NEOPLASMS; RNA, MESSENGER; TREATMENT OUTCOME;

EID: 84899584503     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-33-31     Document Type: Article

References (22)

1. Cancer statistics, 2012. Siegel R, Naishadham D, Jemal A, CA Cancer J Clin 2012 62 1 10 29 10.3322/caac.20138 22237781
2. Human periprostatic adipose tissue promotes prostate cancer aggressiveness in vitro. Ribeiro R, Monteiro C, Cunha V, Oliveira MJ, Freitas M, Fraga A, Príncipe P, Lobato C, Lobo F, Morais A, Silva V, Sanches-Magalhães J, Oliveira J, Pina F, Mota-Pinto A, Lopes C, Medeiros R, J Exp Clin Cancer Res 2012 31 32 10.1186/1756-9966-31-32 22469146
3. Dose escalation using ultra-high dose IMRT in intermediate risk prostate cancer without androgen deprivation therapy: preliminary results of toxicity and biochemical control. Petrongari MG, Landoni V, Saracino B, Gomellini S, Arcangeli S, Iaccarino G, Pinnarò P, Arcangeli G, Strigari L, J Exp Clin Cancer Res 2013 32 1 103 10.1186/1756-9966-32-103 24330467
4. Regulation of secretory vesicle traffic by Rab small GTPases. Fukuda M, Cell Mol Life Sci 2008 65 2801 2813 10.1007/s00018-008-8351-4 18726178
5. Rab GTPases as coordinators of vesicle traffic. Stenmark H, Nat Rev Mol Cell Biol 2009 10 513 525 10.1038/nrm2728 19603039
6. Rab GEFs and GAPs. Barr F, Lambright DG, Curr Opin Cell Biol 2010 22 461 470 10.1016/j.ceb.2010.04.007 20466531
7. Family-wide characterization of the DENN domain Rab GDP-GTP exchange factors. Yoshimura S, Gerondopoulos A, Linford A, Rigden DJ, Barr FA, J Cell Biol 2010 191 367 381 10.1083/jcb.201008051 20937701
8. Rab proteins as membrane organizers. Zerial M, McBride H, Nat Rev Mol Cell Biol 2001 2 107 117 10.1038/35052055 11252952 (Pubitemid 33674039)
9. A novel RAB-5 GDP/GTP exchange factor complexed to Rabaptin-5 links nucleotide exchange to effector recruitment and function. Horiuchi H, Lippe R, McBride HM, Rubino M, Woodman P, Stenmark H, Rybin V, Wilm M, Ashman K, Mann M, Zerial M, Cell 1997 90 1149 1159 10.1016/S0092-8674(00)80380-3 9323142 (Pubitemid 27408528)
10. Seven genes that are differentially transcribed in colorectal tumor cell lines. Nimmrich I, Erdmann S, Melchers U, Finke U, Hentsch S, Moyer MP, Hoffmann I, Muller O, Cancer Lett 2000 160 37 43 10.1016/S0304-3835(00)00553-X 11098082
11. RABEX-5 plays an oncogenic role in breast cancer by activating MMP-9 pathway. Zhang X, Min J, Wang Y, Li Y, Li H, Liu Q, Liang X, Mu P, Li H, J Exp Clin Cancer Res 2013 32 1 52 10.1186/1756-9966-32-52 23941575
12. Clinical significance of NUCB2 mRNA expression in prostate cancer. Zhang H, Qi C, Li L, Luo F, Xu Y, J Exp Clin Cancer Res 2013 32 56 10.1186/1756-9966-32-56 23958433
13. High expression of nucleobindin 2 mRNA: an independent prognostic factor for overall survival of patients with prostate cancer. Zhang H, Qi C, Wang A, Li L, Xu Y, Tumor Biol 2013 35 3 2025 2028
14. Prognostication of prostate cancer based on NUCB2 protein assessment: NUCB2 in prostate cancer. Zhang H, Qi C, Wang A, Yao B, Li L, Wang Y, Xu Y, J Exp Clin Cancer Res 2013 32 77 10.1186/1756-9966-32-77 24422979
15. The development of androgen-independent prostate cancer. Feldman BJ, Feldman D, Nat Rev Cancer 2001 1 1 34 45 10.1038/35094009 11900250 (Pubitemid 33741879)
16. International trends and patterns of prostate cancer incidence and mortality. Hsing AW, Tsao L, Devesa SS, Int J Cancer 2000 85 60 67 10.1002/(SICI)1097-0215(20000101)85:1<60:AID-IJC11>3.0.CO;2-B 10585584
17. Screening for prostate cancer: a review of the ERSPC and PLCO trials. Eckersberger E, Finkelstein J, Sadri H, Margreiter M, Taneja SS, Lepor H, Djavan B, Rev Urol 2009 11 127 133 19918338
18. Annual screening for prostate cancer did not reduce mortality from prostate cancer/Annual screening for prostate cancer did not reduce mortality from prostate cancer. Canfield SE, Evid Based Med 2009 14 104 105 10.1136/ebm.14.4.104
19. Overexpression of LAPTM4B-35: a novel marker of poor prognosis of prostate cancer. Zhang H, Wei Q, Liu R, Qi S, Liang P, Qi C, Wang A, Sheng B, Li L, Xu Y, PLoS One 2014 9 3 91069 10.1371/journal.pone.0091069 24651764
20. CIP2A expression is increased in prostate cancer. Vaarala MH, Väisänen MR, Ristimäki A, J Exp Clin Cancer Res 2010 29 136 10.1186/1756-9966-29-136 20964854
21. In vitro the behaviors of metastasis with suppression of VEGF in human bone metastatic LNCaP-derivative C4-2B prostate cancer cell line. Yang L, You S, Kumar V, Zhang C, Cao Y, J Exp Clin Cancer Res 2012 31 40 10.1186/1756-9966-31- 40 22549243
22. The association between metabolic syndrome and the risk of prostate cancer, high-grade prostate cancer, advanced prostate cancer, prostate cancer-specific mortality and biochemical recurrence. Xiang YZ, Xiong H, Cui ZL, Jiang SB, Xia QH, Zhao Y, Li GB, Jin XB, J Exp Clin Cancer Res 2013 32 9 10.1186/1756-9966-32-9 23406686